Trump and Putin to meet in Alaska on 15 August for Ukraine peace talks
U.S. President Donald Trump announced on Friday that he will meet Russian President Vladimir Putin in Alaska on 15 August to negotiate an end to the c...
Radionuclide therapy using the radioactive element terbium shows promising potential in treating lymphoma, according to recent experimental results from the Paul Scherrer Institute (PSI) in collaboration with Inselspital – Bern University Hospital.
Elisa Rioja-Blanco and Martin Béhé are jointly conducting research at the Center for Radiopharmaceutical Sciences, part of the PSI Center for Life Sciences. The researchers are now refining this type of therapy in order to carry out clinical trials.
Every year, almost 2,000 people in Switzerland are diagnosed with lymphoma, and about 570 of them die from the disease. Researchers at PSI’s Center for Radiopharmaceutical Sciences are now proposing a new therapy that could soon increase the chances of survival for many of those affected: radioimmunotherapy with the nuclide terbium-161.
“The radioactive isotope terbium-161 is attached to an antibody and injected into the bloodstream of the patient,” explains Martin Béhé from the Center for Radiopharmaceutical Sciences, part of the PSI Center for Life Sciences. This antibody latches onto a structure in the body that is particularly common in lymphoma cells: the CD30 receptor. “This brings the radioactive terbium directly to the site of the tumour to kill the cancer cells with its radioactive radiation.” Healthy organs in the body are spared, on the other hand.
In almost a third of all lymphoma patients, the tumour cells produce the CD30 receptor – in these patients the new treatment could be applied. The same is true of T-cell lymphomas, in which the T-lymphocytes of the immune system become cancerous – a disease that has until now been difficult to treat.
Radionuclide therapy is already well established in clinical practice. Hospitals currently carry out this form of cancer treatment with a different radioactive substance: the nuclide lutetium-177. This is used to treat prostate cancer and tumours arising from hormone-producing cells. Radioactive lutetium decays to produce high-energy, high-velocity electrons, called beta particles, which combat larger tumours effectively.
However, individual tumour cells and small clusters of cancer cells elude treatment with lutetium-177 and can lead to a recurrence of the disease. This makes this form of radionuclide therapy unsuitable for lymphoma. In this type of cancer, some of the tumour cells circulate in the bloodstream rather than existing as a larger, localisable tumour.
Terbium-161 has a decisive advantage over lutetium-177: in addition to beta particles, it also emits conversion and Auger electrons. “This radiation has a range of less than one micrometre, or one thousandth of a millimetre. This is the size of a tumour cell,” explains Martin Béhé. Hence, terbium-161 acts on its immediate surroundings, making it particularly suitable for the targeted treatment of smaller tumours.
“Terbium-161 fires more precise bullets, so to speak,” explains Elisa Rioja-Blanco, also from the Center for Radiopharmaceutical Sciences and first author of the study. Even individual cancer cells in the blood could be eliminated without causing severe side effects. “We can also catch small tumour foci that doctors may not even be aware of at the time.”
The isotope has a half-life of 6.9 days, which means that its effect is halved every 6.9 days. This is an advantage for radionuclide therapy: after manufacturing the drug, it can be transported to a hospital without losing too much of its activity on the way. On the other hand, the radiation level decreases rapidly after treatment within a reasonable period of time.
A powerful weapon against cancer cells
The PSI researchers led by Martin Béhé and Elisa Rioja-Blanco produced the active substance, consisting of terbium-161 and an antibody against the CD30 receptor, themselves at PSI. They then tested it in the laboratory on three types of cancer cells that produce CD30 receptors. They found that – depending on the type of cell – the substance was 2 to 43 times as effective at killing the cancer cells than the analogous substance using lutetium-177. Further experiments have shown that this is because the terbium-based drug caused more severe damage to the DNA in the cancer cell, which the cell itself is unable to repair.
The researchers then tested the drug on mice suffering from cancer. “This shows us where the substance accumulates in the body and whether it actually reaches tumours,” explains Elisa Rioja-Blanco. The substance was indeed preferentially absorbed by the tumour tissue. On average, mice treated with terbium-161 survived twice as long as their counterparts injected with a lutetium-177 drug. Some of the mice even ended up completely cancer-free after the treatment.
On the way to clinical trials
Terbium-161 is already being tested as an anti-cancer drug in several clinical trials – the PSI researchers have now for the first time scrutinised it as a potential treatment for lymphoma. “Our results are a good indication that the substance could also prove to be effective against lymphoma in humans,” says Elisa Rioja-Blanco. Clinical studies will hopefully soon show whether this is indeed the case.
The Lymphoma Challenge, organised by ETH Zurich, is providing financial support for the project. The team has now secured follow-on funding from Innosuisse to further investigate and optimise the drug so that it can be commercialised and tested in humans in the future.
The world’s biggest dance music festival faces an unexpected setback as a fire destroys its main stage, prompting a last-minute response from organisers determined to keep the party alive in Boom, Belgium.
According to the German Research Centre for Geosciences (GFZ), a magnitude 5.7 earthquake struck the Oaxaca region of Mexico on Saturday.
China and the Association of Southeast Asian Nations will send an upgraded ‘version 3.0’ free-trade agreement to their heads of government for approval in October, Chinese Foreign Minister Wang Yi said on Saturday after regional talks in Kuala Lumpur.
A resumption of Iraq’s Kurdish oil exports is not expected in the near term, sources familiar with the matter said on Friday, despite an announcement by Iraq’s federal government a day earlier stating that shipments would resume immediately.
Chinese automaker Chery has denied an industry-ministry audit that disqualified more than $53 million in state incentives for thousands of its electric and hybrid vehicles, insisting it followed official guidance and committed no fraud.
Tech giant Google has announced a $1 billion investment to support Artificial Intelligence (AI) education and research at universities across the United States.
What shapes human nature? Why do some people act with compassion while others turn cruel? For centuries, thinkers — from philosophers and playwrights to theologians and psychologists — have grappled with these timeless questions, searching for what lies at the heart of good and evil.
A new skin cancer drug has been developed using a genetically engineered virus that targets and replicates only cancer cells. That's according to public broadcaster NHK who said that researchers in Japan found that 77.8% of those tested, improved.
Adults are inhaling around 68,000 microplastic particles each day, researchers warn, over 100 times previous estimates.
Americans will soon be able to access and share their medical records through a new “digital health tech ecosystem”, unveiled by U.S. President Donald Trump in partnership with more than 60 major technology companies.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment